<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534270</url>
  </required_header>
  <id_info>
    <org_study_id>EASODICWP.01</org_study_id>
    <nct_id>NCT04534270</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dapagliflozin in Children With Proteinuria</brief_title>
  <official_title>Efficacy and Safety of Dapagliflozin in Non-diabetic Children With Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in&#xD;
      children with proteinuria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in 24-hr proteinuria after a 4 weeks treatment with dapagliflozin</measure>
    <time_frame>From baseline to weeks 4</time_frame>
    <description>Urine will be collected for 24 hours and total urinary protein will be detected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in 24-hr proteinuria after a 12 weeks treatment with dapagliflozin</measure>
    <time_frame>From baseline to weeks 12</time_frame>
    <description>Urine will be collected for 24 hours and total urinary protein will be detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in eGFR after a 12 weeks treatment with dapagliflozin</measure>
    <time_frame>Measured at baseline, weeks 4, weeks 8, weeks 12</time_frame>
    <description>eGFR are repeated measurement data and will be evaluated by Schwartz formula（k*height（cm)/creatinine(umol/L), k=36.5）</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight&gt;30kg), for 12 weeks</description>
    <arm_group_label>Dapagliflozin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 years to 18 years;&#xD;
&#xD;
          -  Urinary protein excretion &gt; 0.2g in a 24-hr urine collection;&#xD;
&#xD;
          -  eGFR≥60 ml/min/1.73m2;&#xD;
&#xD;
          -  No history of diabetes;&#xD;
&#xD;
          -  On stable doses of ACE inhibitors or angiotensin receptor blockers (ARBs) for &gt; 1&#xD;
             month;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving immunosuppressive therapy within three months prior to enrolment.&#xD;
&#xD;
          -  Blood pressure less than 5th percentile of the same gender, age, and height -&#xD;
&#xD;
          -  Leukocyte and/or nitrite positive urinalysis that is untreated;&#xD;
&#xD;
          -  History of organ transplantation, cancer, liver disease;&#xD;
&#xD;
          -  Evidence of hepatic disease as determined by any one of the following: ALT or AST&#xD;
             values exceeding 3x ULN at the screening visit;&#xD;
&#xD;
          -  History of noncompliance to medical regimens or unwillingness to comply with the study&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Xu, Professor</last_name>
    <phone>+86-02164932829</phone>
    <email>hxu@shmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiaojiao Liu, Doctor</last_name>
    <phone>+86-02164932829</phone>
    <email>liujiaojiao137@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Xu, Professor</last_name>
      <phone>+86-02164932829</phone>
      <email>hxu@shmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hong Xu，MD.PhD</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>proteinuria</keyword>
  <keyword>SGLT2i</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

